JAK2 V617F detected in two B‑cell chronic lymphocytic leukemia patients without coexisting Philadelphia chromosome‑negative myeloproliferative neoplasms: A report of two cases

Yang,Yi‑Ning; Qin,You‑Wen; Wang,Chun

doi:10.3892/ol.2014.2168

JAK2 V617F detected in two B‑cell chronic lymphocytic leukemia patients without coexisting Philadelphia chromosome‑negative myeloproliferative neoplasms: A report of two cases

Authors:
- Yi‑Ning Yang
- You‑Wen Qin
- Chun Wang
View Affiliations

Affiliations: Department of Hematology, Shanghai First People's Hospital, Medical College, Shanghai Jiao Tong University, Shanghai 200080, P.R. China
Published online on: May 22, 2014 https://doi.org/10.3892/ol.2014.2168
Pages: 841-844

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The JAK2 V617F mutation has been observed in patients with Philadelphia chromosome‑negative myeloproliferative neoplasms (Ph‑MPNs), including polycythemia vera, essential thrombocythemia and idiopathic myelofibrosis. This mutation has also been observed in a small number of other myeloid malignancies, such as acute myeloid leukemia, chronic myeloid leukemia and myelodysplastic syndrome. The JAK2 V617F allele has rarely been evaluated in lymphoproliferative disorders. In total, 28 JAK2 V617F‑positive B‑cell lymphocytic leukemia (B‑CLL) patients have previously been reported and all presented with Ph‑MPN concomitantly. However, following investigation of the JAK2 V617F mutation in 63 B‑CLL patients at the Shanghai First People's Hospital (Shanghai, China) between January 2008 and December 2012 via allele‑specific polymerase chain reaction, two B‑CLL patients without a history of Ph‑MPN were identified to carry the JAK2 V617F allele.

View Figures

View References

1	Baxter EJ, Scott LM, Campbell PJ, et al; Cancer Genome Project. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 365:1054–1061. 2005.
2	Jelinek J, Oki Y, Gharibyan V, et al: JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia. Blood. 106:3370–3373. 2005.
3	Levine RL, Loriaux M, Huntly BJ, et al: The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia. Blood. 106:3377–3379. 2005.
4	Wang YL, Lee JW, Kui JS, et al: Evaluation of JAK2 in B and T cell neoplasms: identification of JAK2(V617F) mutation of undetermined significance (JMUS) in the bone marrow of three individuals. Acta Haematol. 118:209–214. 2007.
5	Zhao W, Gao R, Lee J, Xing S, et al: Relevance of JAK2V617F positivity to hematological diseases - survey of samples from a clinical genetics laboratory. J Hematol Oncol. 4:42011.
6	Stijnis C, Kroes WG, Balkassmi S, et al: No evidence for JAK2(V617F) mutation in monoclonal B cells in 2 patients with polycythaemia vera and concurrent monoclonal B cell disorder. Acta Haematol. 128:183–186. 2012.
7	Eskazan AE, Salihoglu A, Diz-Kucukkaya R, et al: Chronic lymphocytic leukemia developing in a patient with Janus kinase 2 V617F mutation positive myeloproliferative neoplasm. Ann Hematol. 91:305–306. 2012.
8	Kodali S, Chen C, Rathnasabapathy C and Wang JC: JAK2 mutation in a patient with CLL with coexistent myeloproliferative neoplasm (MPN). Leuk Res. 33:e236–e239. 2009.
9	Tabaczewski P, Nadesan S and Lim SH: Zap-70 positive chronic lymphocytic leukemia co-existing with Jak 2 V671F positive essential thrombocythemia: a common defective stem cell? Leuk Res. 33:854–855. 2009.
10	Laurenti L, Tarnani M, Nichele I, et al: The coexistence of chronic lymphocytic leukemia and myeloproliferative neoplasms: a retrospective multicentric GIMEMA experience. Am J Hematol. 86:1007–1012. 2011.
11	Wei J, Wang C, Qin YW, et al: JAK2 V617F positive essential thrombocythemia developing in a patient with CD5⁻ chronic lymphocytic leukemia. Chin Med J (Engl). 125:2076–2079. 2012.
12	Swierczek S, Nausova J, Jelinek J, et al: Concomitant JAK2 V617F-positive polycythemia vera and B-cell chronic lymphocytic leukemia in three patients originating from two separate hematopoietic stem cells. Am J Hematol. 88:157–158. 2013.
13	Musolino C, Allegra A, Penna G, et al: Absence of the V617F JAK2 mutation in the lymphoid compartment in a patient with essential thrombocythemia and B-chronic lymphocytic leukemia and in two relatives with lymphoproliferative disorders. Acta Haematol. 122:46–49. 2009.
14	Henry L, Carillo S, Jourdan E, et al: Association of essential thrombocythemia and chronic lymphocytic leukemia: absence of the V617F JAK2 mutation in the lymphoid compartment. Am J Hematol. 82:500–501. 2007.
15	Hussein K, Brakensiek K, Ballmaier M, et al: B-CLL developing in a patient with PV is not affected by V617F mutation of the Janus kinase 2. Eur J Haematol. 77:539–541. 2006.
16	Hallek M: Chronic lymphocytic leukemia: 2013 update on diagnosis, risk stratification and treatment. Am J Hematol. 88:803–816. 2013.
17	Zehentner BK, Loken MR and Wells DA: JAK2V617F mutation can occur exclusively in the erythroid lineage and be absent in granulocytes and progenitor cells in classic myeloproliferative disorders. Am J Hematol. 81:806–807. 2006.
18	Ishii T, Bruno E, Hoffman R and Xu M: Involvement of various hematopoietic-cell lineages by the JAK2V617F mutation in polycythemia vera. Blood. 108:3128–3134. 2006.
19	Larsen TS, Christensen JH, Hasselbalch HC and Pallisgaard N: The JAK2 V617F mutation involves B- and T-lymphocyte lineages in a subgroup of patients with Philadelphia-chromosome negative chronic myeloproliferative disorders. Br J Haematol. 136:745–751. 2007.
20	Delhommeau F, Dupont S, Tonetti C, et al: Evidence that the JAK2 G1849T (V617F) mutation occurs in a lymphomyeloid progenitor in polycythemia vera and idiopathic myelofibrosis. Blood. 109:71–77. 2007.
21	Bogani C, Guglielmelli P, Antonioli E, et al: B-, T-, and NK-cell lineage involvement in JAK2V617F-positive patients with idiopathic myelofibrosis. Haematologica. 92:258–259. 2007.
22	Khwaja A: The role of Janus kinases in haemopoiesis and haematological malignancy. Br J Haematol. 134:366–384. 2006.
23	Kaushansky K: On the molecular origins of the chronic myeloproliferative disorders: it all makes sense. Blood. 105:4187–4190. 2005.
24	James C, Ugo V, Le Couédic JP, et al: A unique clonal JAK2 mutation leading to constitutive signaling causes polycythaemia vera. Nature. 434:1144–1148. 2005.
25	dos Santos NR and Ghysdael J: A transgenic mouse model for TEL-JAK2-induced B-cell lymphoma/leukemia. Leukemia. 20:182–185. 2006.
26	Adélaïde J, Pérot C, Gelsi-Boyer V, et al: A t(8;9) translocation with PCM1-JAK2 fusion in a patient with T-cell lymphoma. Leukemia. 20:536–537. 2006.
27	Zhang Q, Raghunath PN, Xue L, et al: Multilevel dysregulation of STAT3 activation in anaplastic lymphoma kinase-positive T/null-cell lymphoma. J Immunol. 168:466–474. 2002.
28	Melzner I, Bucur AJ, Brüderlein S, et al: Biallelic mutation of SOCS-1 impairs JAK2 degradation and sustains phospho-JAK2 action in the MedB-1 mediastinal lymphoma line. Blood. 105:2535–2542. 2005.
29	Sidon P, El Housni H, Dessars B and Heimann P: The JAK2V617F mutation is detectable at very low level in peripheral blood of healthy donors. Leukemia. 20:16222006.
30	Xu X, Zhang Q, Luo J, et al: JAK2(V617F): Prevalence in a large Chinese hospital population. Blood. 109:339–342. 2007.